Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
11 Julho 2024 - 9:21AM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2024/7/11/Aspose.Words.95e0a3b2-f7ce-4856-bda2-c7f957144e55.001.png)
Cannabix Technologies and Omega Laboratories Inc.
Provide Positive Developments on Marijuana Breathalyzer
Testing
Vancouver, British Columbia, Canada -- July 11, 2024 --
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix")
reports that early testing by Omega Laboratories Inc ("Omega
Laboratories" or "Omega") with the Company's marijuana breathalyzer
technology have garnered positive results. Omega has commenced
pre-validation scoping work to establish limits of detection (LOD)
and limits of quantification (LOQ) as well as the cutoff level for
the detection of delta-9 THC (primary psychoactive ingredient in
cannabis) in breath. Recently, Cannabix entered into a strategic
partnership and development agreement with Omega Laboratories to
advance the development and commercialization of the Cannabix
marijuana breathalyzer technology. Omega Laboratories is an
international industry leader in forensic drugs of abuse testing
with multiple international certifications and accreditations.
Highlights:
-
Omega scientists have established a delta-9 THC calibration curve
with samples obtained from the Cannabix Breath Collection Unit
(BCU) for the purposes of quantification using Omega's preexisting
and well-established extraction and detection processes.
-
Thus far, Omega scientists have been able to detect and quantify
delta-9 THC in the low picogram range – a level of detection low
enough for detecting drug compounds in breath.
-
Omega scientists have consistently detected and quantified delta-9
THC from breath samples collected from subjects utilizing the
Cannabix BCU.
-
Omega scientists have developed a test method for a breath sample
that successfully detects and differentiates between delta-9 THC,
delta-8 THC, CBN and CBD. Cannabix and Omega have begun working
together on multiple fronts including hardware refinement,
marketing and preparing numerous validation studies.
Omega
Laboratories is headquartered in Ohio, USA in a
state-of-the-art facility providing drugs of abuse testing to over
6,000 clients worldwide, including several Fortune 500 companies,
police, highway patrol, court systems, military organizations, and
school systems. Omega also has one of the largest Third-Party
Administrator (TPA) client lists in America.
Rav
Mlait, CEO of Cannabix stated, "We are off to a terrific start
alongside Omega Laboratories. We are working together to help
provide a comprehensive marijuana breath testing solution for
employers, law enforcement and others. Public policy in the United
States towards cannabis is garnering additional attention as we
move closer to the U.S. presidential election later this year where
cannabis legalization could become a hot topic. Recently the DEA
proposed rules to reclassify cannabis from a schedule I to a
schedule III substance, further bolstering our expectation that the
demand for marijuana drug testing will continue to increase."
About Omega Laboratories, Inc.
Omega
Laboratories, headquartered in Mogadore, Ohio with additional
state-of-the-art facilities in Ontario and British Columbia, Canada
provides laboratory-based advanced testing solutions to over 6,000
clients worldwide. Omega Laboratories has over 24 years of
experience in pioneering innovative drug testing methodologies,
specializing in the detection of drugs of abuse utilizing Hair,
Oral Fluid and Urine. Omega continues to innovate with the launch
of their Technical Solutions portfolio that incorporates a
paperless online Custody & Control Form system (oCCF) in eight
languages, licensure of a Laboratory Information Management System
(LIMS) designed specifically for Toxicology and powers new
laboratories in countries that have demand for local service
providers.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol
breathalyzer technologies for law enforcement, workplaces and
laboratories. Cannabix is developing delta-9 THC and alcohol
screening devices. Delta-9 THC is the primary psychoactive
ingredient in cannabis. Breath testing for delta-9 THC would allow
employers and law enforcement to identify recent marijuana
use. Cannabix is the developer of its Breath Logix Series of
breath alcohol detection devices for employers and a range of
other settings.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc
For
further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates," "plan," "continue," "expect,"
"project," "intend," "believe," "anticipate," "estimate," "may,"
"will," "potential," "proposed," "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. Forward-looking statements in this news release
include, but are not limited to, statements relating to: the
achievement of any or all of the goals and aims of the Agreement;
the achievement of the milestone developments and perceived
benefits of the Agreement described in this news release; final
development of a commercial or prototype product(s); the successful
trial or pilot of company technologies; the commercialization of
the Company's products; the negotiation and potential entry into
additional agreements with Omega; and the completion of future
financings. There are numerous risks and uncertainties that could
cause actual results and the Company's plans and objectives to
differ materially from those expressed in the forward-looking
information. Important factors that could cause actual results to
differ materially from those expressed in the forward-looking
information include (but are note limited to): adverse market
conditions; risks regarding protection of proprietary technology;
the ability of the Company to complete future financings; the
ability of the Company to develop and market its future product;
risks regarding government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition;
that Omega may not complete all or any of the milestones as
contemplated in the Agreement; that the CSE may not approve the
issuance of the securities; that the Company's development of
breathalyzer technology will provide any benefit to the Company;
there is no assurance that any proposed new products will be built,
will be successful in beta testing or clinical trials; there is no
assurance that the Company will enter into any partnerships to
advance any of its corporate initiatives or technologies; there is
no assurance that any "patent pending" or "provisional patents"
technologies licensed by the Company or owned by the Company will
receive patent status by regulatory authorities; the Company is not
currently selling commercial breathalyzers and there is no
assurance that the Company ever will; and other factors beyond the
control of the Company. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
The CSE
has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix Technologies (CSE:BLO)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Cannabix Technologies (CSE:BLO)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024